35 / 92
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 27, No 4, July/August 2016
AFRICA
237
This work was supported by the Natural Science Foundation of Anhui (No
090413111, 1508085MH149) and the Wuhu municipal scientific research
projects (No 2013 cxy04). The experimental research work was completed at
the Clinical Testing and Diagnosis Experimental Centre of Bengbu Medical
College and the key laboratory of bioactive macromolecules of Wangnan
Medical College in Anhui province.
References
1.
Xu N, Dahlback B. A novel human apolipoprotein (apoM).
J Biol Chem
1999;
274
:
31286–31290.
2.
Dahlback B, Nielsen LB. Apolipoprotein M – a novel player in high-
density lipoprotein metabolism and atherosclerosis.
J Curr Opin Lipidol
2006;
17
:
291–295.
3.
Christoffersen C, Obinata H, Kumaraswamy SB, Galvani S, Ahnström
J, Sevvana M,
et al
. Endothelium-protective sphingosine-1-phosphate
provided by HDL-associated apolipoprotein M.
Proc Natl Acad Sci U
S A
2011;
108
:
9613–9618.
4.
Wolfrum C, Poy MN, Stoffel M. Apolipoprotein M is required for
pre beta-HDL formation and cholesterol efflux to HDL and protects
against atherosclerosis.
Nature Med
2005;
11
:
418–422.
5.
Christoffersen C, Nielsen LB, Axler O, Andersson A, Johnsen AH,
Dahlbäck B. Isolation and characterization of human apolipoprotein
M-containing lipoproteins.
J Lipid Res
2006;
47
:
1833–1843.
6.
Christoffersen C, Nielsen LB. Apolipoprotein M – a new biomarker in
sepsis.
Crit Care
2012;
16
:
126.
7.
Bjrn D, Nielsen LB. Apolipoprotein M: a novel player in high density
lipoprotein metabolism and atherosclerosis.
Curr Opin Lipidol
2006;
17
:
291–295.
8.
Feingold KR, Shigenaga JK, Chui LG, Moser A, Khovidhunkit W,
Grunfeld C. Infection and inflammation decrease apolipoprotein M
expression.
Atherosclerosis
2008;
199
:
19–26.
9.
Xu N, Hurtig M, Zhang XY, Ye Q, Nilsson-Ehle P. Transforming growth
factor-beta downregulates apolipoprotein M in HepG2 cells.
Biochim
Biophys Acta
2004;
1683
:
33–37.
10. Han M, Zhong YL. Transcription factor AP-2 and its Roles in Cancer.
Acta Laser Biol Sinica
2004;
13
:
462–464.
11. Huang QC, Cao JH. The role of activating protein-2 transcription
factors in breast cancer.
Basic Clinical Med
2012;
32
:
841–843.
12. Hilger-Eversheim K, Moser M, Schorle H, Buettner R. Regulatory roles
of AP-2 transcription factors in vertebrate development, apoptosis and
cell cycle control.
Gene
2000;
260
:
1–12.
13. Zhao F, Satoda M, Licht JD, Hayashizaki Y, Gelb BD. Cloning and
characterization of a novel mouse AP-2 transcription factor, AP-2delta,
with unique DNA binding and transactivation properties.
J Biol Chem
2001;
276
:
40755–40760.
14. Tummala R, Romano RA, Fuchs E, Sinha S. Molecular cloning and
characterization of AP-2 epsilon, a fifth member of the AP-2 family.
Gene
2003;
321
:
93–102.
15. Lu G. The role of AP-2alpha in atherosclerosis and HeLa apopto-
sis. Hunan: Biochemistry and molecular biology of Hunan Normal
University Teaching and Research Section, 2008: 70–74.
16. Zhou JW, Tsui SK, NgMC, GengH, Li SK, SoWY,
et al
. Apolipoprotein
M gene (APOM) polymorphism modifies metabolic and disease traits in
type 2 diabetes.
PLoS One
2011;
6
:
e17324.
17. Wu X, Niu N, Brismar K, Zhu X, Wang X, Efendic S,
et al
.
Apolipoprotein M promoter polymorphisms alter promoter activity and
confer the susceptibility to the development of type 1 diabetes.
Clin Biol
Chem
2009;
42
:
17–21.
18. Xu WW, Zhang Y, Tang YB, Xu YL, Zhu HZ, Ferro A,
et al
. A genetic
variant of apolipoprotein M increases susceptibility to coronary artery
disease in a Chinese population.
Clin Exp Pharmacol Physiol
2008;
35
:
546–551.
19. Jiao GQ, Yuan ZX, Xue YS, Yang CJ, Lu CB, Lu ZQ,
et al
. A prospec-
tive evaluation of apolipoprotein M gene T-778C polymorphism in
relation to coronary artery disease in Han Chinese.
Clin Biol Chem
2007;
40
:
1108–1112.
20. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High
density lipoprotein as a protective factor against coronary heart disease.
The Framingham Study.
Am J Med
1977;
62
:
707–714.
21. Elsøe S, Christoffersen C, Luchoomun J, Turner S, Nielsen LB.
Apolipoprotein M promotes mobilization of cellular cholesterol
in vivo
.
Biochim Biophys Acta
2013;
1831
:
1287–1292.
22. Faber K, Hvidberg V, Moestrup SK, Dahlbäck B, Nielsen LB. Megalin
is a receptor for apolipoprotein M, and kidney-specific megalin-defi-
ciency confers urinary excretion of apolipoprotein M.
Mol Endocrinol
2006;
20
:
212–218.
23. Lee CS, Friedman JR, Fulmer JT, Kaestner KH. The initiation of liver
development is dependent on Foxa transcription factors.
Nature
2005;
435
:
944–947.
24. Wolfrum C, Howell JJ, Ndungo E, Stoffel M. Foxa2 activity increases
plasma high density lipoprotein levels by regulating apolipoprotein M.
J
Biol Chem
2008;
283
: 16940–16949.
25. Zhang X, Zhu Z, Luo G, Zheng L, Nilsson-Ehle P, Xu N. Liver X recep-
tor agonist downregulates hepatic apoM expression
in vivo
and
in vitro
.
Biochem Biophys Res Commun
2008;
371
:
114–117.
26. Calayir E, Becker TM, Kratzer A, Ebner B, Panzenböck U, Stefujl J,
et
al
. LXR-agonists regulate ApoM expression differentially in liver and
intestine.
Curr Pharm Biotech
2008;
9
:
516–521.
27. Xu N, Nilsson-Ehle P, Hurtig M, Ahrén B. Both leptin and leptin-
receptor are essential for apolipoprotein M expression
in vivo. Biochem
Biophys Res Commun
2004;
321
: 916–921.
28. Wolfrum C, Asilmaz E, Luca E, Friedman JM, Stoffel M. Foxa2 regu-
lates lipid metabolism and ketogenesis in the liver during fasting and in
diabetes.
Nature
2004;
432
: 102710–102732.